Publications by authors named "Lindsay McKay"

Article Synopsis
  • Next-generation sequencing (NGS) struggles to fully capture the critical 5' and 3' ends of RNA virus genomes, which are essential for understanding their replication and transcription.
  • The newly developed ViBE-Seq method offers high-resolution sequencing of these genome ends using minimal RNA, improving the reliability of data collection for RNA viruses like Ebola and Marburg.
  • ViBE-Seq also helps identify the activity of different reverse transcriptases, providing a comprehensive approach to sequencing emerging viral genomes.
View Article and Find Full Text PDF

Monoclonal antibodies (mAbs) are an important class of antiviral therapeutics. MAbs are highly selective, well tolerated, and have long in vivo half-life as well as the capacity to induce immune-mediated virus clearance. Their activities can be further enhanced by integration of their variable fragments (Fvs) into bispecific antibodies (bsAbs), affording simultaneous targeting of multiple epitopes to improve potency and breadth and/or to mitigate against viral escape by a single mutation.

View Article and Find Full Text PDF

The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 vaccines highlights the need for continued development of broadly protective vaccines for the future. Here, we developed two messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccines, TU88mCSA and ALCmCSA, using the ancestral SARS-CoV-2 spike sequence, optimized 5' and 3' untranslated regions (UTRs), and LNP combinations. Our data showed that these nanocomplexes effectively activate CD4 and CD8 T cell responses and humoral immune response and provide complete protection against WA1/2020, Omicron BA.

View Article and Find Full Text PDF

Coronavirus disease 2019 (COVID-19) has had devastating effects worldwide, with particularly high morbidity and mortality in outbreaks on residential care facilities. Amantadine, originally licensed as an antiviral agent for therapy and prophylaxis against influenza A virus, has beneficial effects on patients with Parkinson's disease and is used for treatment of Parkinson's disease, multiple sclerosis, acquired brain injury, and various other neurological disorders. Recent observational data suggest an inverse relationship between the use of amantadine and COVID-19.

View Article and Find Full Text PDF

Despite the vast diversity of the antibody repertoire, infected individuals often mount antibody responses to precisely the same epitopes within antigens. The immunological mechanisms underpinning this phenomenon remain unknown. By mapping 376 immunodominant "public epitopes" at high resolution and characterizing several of their cognate antibodies, we concluded that germline-encoded sequences in antibodies drive recurrent recognition.

View Article and Find Full Text PDF

Licensed COVID-19 vaccines ameliorate viral infection by inducing production of neutralizing antibodies that bind the SARS-CoV-2 Spike protein and inhibit viral cellular entry. However, the clinical effectiveness of these vaccines is transitory as viral variants escape antibody neutralization. Effective vaccines that solely rely upon a T cell response to combat SARS-CoV-2 infection could be transformational because they can utilize highly conserved short pan-variant peptide epitopes, but a mRNA-LNP T cell vaccine has not been shown to provide effective anti-SARS-CoV-2 prophylaxis.

View Article and Find Full Text PDF

Monoclonal antibodies are an efficacious therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, rapid viral mutagenesis led to escape from most of these therapies, outlining the need for an antibody cocktail with a broad neutralizing potency. Using an unbiased interrogation of the memory B cell repertoire of patients with convalescent COVID-19, we identified human antibodies with broad antiviral activity in vitro and efficacy in vivo against all tested SARS-CoV-2 variants of concern, including Delta and Omicron BA.

View Article and Find Full Text PDF

Neutralizing antibodies that recognize the SARS-CoV-2 spike glycoprotein are the principal host defense against viral invasion. Variants of SARS-CoV-2 bear mutations that allow escape from neutralization by many human antibodies, especially those in widely distributed ("public") classes. Identifying antibodies that neutralize these variants of concern and determining their prevalence are important goals for understanding immune protection.

View Article and Find Full Text PDF

Following acute HCV infection, the virus establishes a chronic disease in the majority of patients whilst few individuals clear the infection spontaneously. The precise mechanisms that determine chronic HCV infection or spontaneous clearance are not completely understood but are proposed to be driven by host and viral genetic factors as well as HCV encoded immunomodulatory proteins. Using the HIV-1 LTR as a tool to measure NF-κB activity, we identified that the HCV E1E2 glycoproteins and more so the E2 protein down-modulates HIV-1 LTR activation in 293T, TZM-bl and the more physiologically relevant Huh7 liver derived cell line.

View Article and Find Full Text PDF
Article Synopsis
  • Many studies have looked at how different variants of SARS-CoV-2 affect the body's neutralizing antibodies, especially after these variants become the dominant strains.
  • This research highlights that the virus can undergo multiple mutations at once in the receptor binding domain (RBD), making it harder for antibodies, from vaccines or treatments, to neutralize the virus.
  • Additionally, a specific antibody was found to neutralize various variants, but the virus can still develop ways to evade this by adding sugar molecules to its structure, suggesting that escape variants will keep emerging as SARS-CoV-2 evolves.
View Article and Find Full Text PDF

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unprecedented global health crisis, resulting in a critical need for effective vaccines that generate protective antibodies. Protein subunit vaccines represent a promising approach but often lack the immunogenicity required for strong immune stimulation. To overcome this challenge, it is first demonstrated that advanced biomaterials can be leveraged to boost the effectiveness of SARS-CoV-2 protein subunit vaccines.

View Article and Find Full Text PDF
Article Synopsis
  • - The study focuses on creating a purified anti-Ebola virus intravenous immunoglobulin (IVIG) from pooled convalescent plasma, leveraging its potential for treating viral diseases like Ebola.
  • - Researchers used an ELISA method to measure immunoglobulin levels and conducted neutralization tests, finding a significant boost in the effectiveness of purified IVIG compared to the pooled plasma.
  • - The results indicated that the purified IVIG improved survival rates in infected mice, suggesting its potential for clinical trials and wider applications against other emerging viruses.
View Article and Find Full Text PDF
Article Synopsis
  • * Researchers analyzed memory B cell receptors from 19 recovered COVID-19 patients and identified seven main groups of antibodies that target specific regions of the virus.
  • * Although some SARS-CoV-2 variants have evaded neutralization by many potent antibodies, certain antibodies still bind effectively, indicating that various components of the immune response contribute to long-term protection against evolving strains.
View Article and Find Full Text PDF

Many individuals mount nearly identical antibody responses to SARS-CoV-2. To gain insight into how the viral spike (S) protein receptor-binding domain (RBD) might evolve in response to common antibody responses, we studied mutations occurring during virus evolution in a persistently infected immunocompromised individual. We use antibody Fab/RBD structures to predict, and pseudotypes to confirm, that mutations found in late-stage evolved S variants confer resistance to a common class of SARS-CoV-2 neutralizing antibodies we isolated from a healthy COVID-19 convalescent donor.

View Article and Find Full Text PDF
Article Synopsis
  • - Memory B cells can produce antibodies that protect against repeated infections of SARS-CoV-2, but their effectiveness against variant strains is not fully understood.
  • - Researchers analyzed monoclonal antibodies from 19 recovered COVID-19 patients and identified 7 main groups that target similar parts of the virus's spike protein.
  • - The study reveals how different antibodies interact with various SARS-CoV-2 strains and highlights the significance of diverse immune recognition in combating new variants.
View Article and Find Full Text PDF

Effective intervention strategies are urgently needed to control the COVID-19 pandemic. Human angiotensin-converting enzyme 2 (ACE2) is a membrane-bound carboxypeptidase that forms a dimer and serves as the cellular receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ACE2 is also a key negative regulator of the renin-angiotensin system that modulates vascular functions.

View Article and Find Full Text PDF

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has devastated global public health systems and economies, with over 52 million people infected, millions of jobs and businesses lost, and more than 1 million deaths recorded to date. Contact with surfaces contaminated with droplets generated by infected persons through exhaling, talking, coughing and sneezing is a major driver of SARS-CoV-2 transmission, with the virus being able to survive on surfaces for extended periods of time. To interrupt these chains of transmission, there is an urgent need for devices that can be deployed to inactivate the virus on both recently and existing contaminated surfaces.

View Article and Find Full Text PDF

The SARS-CoV-2 viral spike (S) protein mediates attachment and entry into host cells and is a major target of vaccine and drug design. Potent SARS-CoV-2 neutralizing antibodies derived from closely related antibody heavy chain genes (IGHV3-53 or 3-66) have been isolated from multiple COVID-19 convalescent individuals. These usually contain minimal somatic mutations and bind the S receptor-binding domain (RBD) to interfere with attachment to the cellular receptor angiotensin-converting enzyme 2 (ACE2).

View Article and Find Full Text PDF

Effective intervention strategies are urgently needed to control the COVID-19 pandemic. Human angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase that forms a dimer and serves as the cellular receptor for SARS-CoV-2. It is also a key negative regulator of the renin-angiotensin system (RAS), conserved in mammals, which modulates vascular functions.

View Article and Find Full Text PDF

Direct sensing in liquids using CMOS-integrated optical and electrical sensors is attractive for lab-on-chip applications, where close physical proximity between sample and sensor can obviate optical lenses, enhance electrical sensitivity, and decrease noise due to parasitics. However, controlled delivery of fluid samples to the chip surface presents an ongoing challenge for lab-on-CMOS development, where traditional wire-bond packaging prevents integration of planar microfluidics. In this paper, we present a method for scalable heterogeneous integration of microfluidic channels and silicon-integrated circuit substrates using a commercial fan-out wafer-level packaging approach.

View Article and Find Full Text PDF

Sebaceous adenitis is an inflammatory skin disease of unknown etiology that leads to a poor haircoat. It occurs mostly in young adult to middle-aged dogs. Clinical signs vary in severity and distribution among breeds and types of haircoat.

View Article and Find Full Text PDF
Perianal fistulas.

Compend Contin Educ Vet

September 2011

Perianal fistulas are a chronic, debilitating disease that requires lifelong monitoring and, potentially, lifelong treatment. Lesions are characterized by ulcerations with draining fistulous tracts around the anal region. Most dogs experience significant pain and discomfort with this condition.

View Article and Find Full Text PDF

Pemphigus foliaceus (PF) is an immune-mediated disease that causes pustules and crusted lesions, most commonly on the pinnae, nasal planum, periocular area, chin, and feet of affected cats. Acantholytic cells caused by degradation of intercellular adhesions are often seen on cytology but are not pathognomonic for PF. A definitive diagnosis is made based on histopathology showing subcorneal pustules with nondegenerate neutrophils and acantholytic cells.

View Article and Find Full Text PDF